Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

NCT02843074 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: elotuzumab
DRUG: Lenalidomide
DRUG: Dexamethasone
PROCEDURE: autologous stem cell transplantation

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]